Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 151

Sort by

Sort Order Select

Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz

Blood (2024) 144 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2024-205697

Published: 2024

Journal Articles

Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial

Blood (2024) 144 (Supplement 1): 340.

https://doi.org/10.1182/blood-2024-205046

Published: 2024

Journal Articles

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2024-210053

Published: 2024

Journal Articles

Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 2336.

https://doi.org/10.1182/blood-2024-202741

Published: 2024

Journal Articles

High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Blood (2024) 144 (Supplement 1): 1707.

https://doi.org/10.1182/blood-2024-194144

Published: 2024

Journal Articles

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience

Efrat Luttwak, Swetha Kambhampati, Esther Drill, Nivetha Ganesan, Liron Hofstetter, Ronit Gurion, Shlomzion Aumann, Arnon Haran, Mika Geva, Marc Panossian, Robert Stuver, Paul A. Hamlin, Ariela Noy, Alex F. Herrera, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 1668.

https://doi.org/10.1182/blood-2024-212085

Published: 2024

Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Blood (2024) 144 (Supplement 1): 573.

https://doi.org/10.1182/blood-2024-198008

Published: 2024

Journal Articles

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Raphael Steiner, Liana Nikolaenko, Swetha Kambhampati, Niloufer Khan, Ranjit Nair, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S Pardee, Sanjeev Luther, Win Su Thet, Shreya Vemuri, Ariela Noy

Blood (2024) 144 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2024-202459

Published: 2024

Journal Articles

Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes

Manik Uppal, Ashwath Gurumurthi, Paul A. Hamlin, Lorenzo Falchi, Steven Horwitz, Anita Kumar, Ariela Noy, Jennifer Kimberly Lue, Pallawi Torka, Maria E. Arcila, Ahmet Dogan, Brandon S. Imber, Joachim Yahalom, Olivier Elemento, Andrew D. Zelenetz, Gilles Salles, Erel Joffe

Blood (2024) 144 (Supplement 1): 4346.

https://doi.org/10.1182/blood-2024-198931

Published: 2024

Journal Articles

Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2024-205803

Published: 2024

Journal Articles

A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign

Blood (2024) 144 (Supplement 1): 4474.

https://doi.org/10.1182/blood-2024-210711

Published: 2024

Journal Articles

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Blood (2024) 144 (Supplement 1): 4434.

https://doi.org/10.1182/blood-2024-210689

Published: 2024

Journal Articles

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2024-203857

Published: 2024

Journal Articles

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Ariela Noy, Win Su Thet, Shreya Vemuri, Venkatraman Seshan, Connie Lee Batlevi, Zachary D. Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Thomas M. Habermann, Paul A. Hamlin, Erel Joffe, Jennifer Kimberly Lue, Matthew Matasar, Maria Lia Palomba, Andrew D. Zelenetz, Gilles Salles

Blood (2024) 144 (Supplement 1): 6352.

https://doi.org/10.1182/blood-2024-211730

Published: 2024

Journal Articles

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 6520.

https://doi.org/10.1182/blood-2024-210617

Published: 2024

Journal Articles

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Blood (2024) 144 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2024-210657

Published: 2024

Journal Articles

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Blood (2024) 144 (Supplement 1): 569.

https://doi.org/10.1182/blood-2024-202537

Published: 2024

Journal Articles

Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Ariela Noy, Stefan K. Barta, Deukwoo Kwon, Robert Baiocchi, Juan Carlos Ramos, Paul Rubinstein, Amy Chadburn, Richard F. Ambinder

Blood (2024) 144 (Supplement 1): 870.

https://doi.org/10.1182/blood-2024-211388

Published: 2024

Journal Articles

Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset

Ariela Noy, Robert Ohgami, Nikhil C. Munshi, Imran Siddiqi, Kelley C. Dacus, Alicia Watson Saltis, Francis Shupo, Nicole Princic, Kristin Evans, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 797.

https://doi.org/10.1182/blood-2024-201745

Published: 2024

Journal Articles

Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

Blood (2023) 142 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2023-187911

Published: 2023

NARROW

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes

Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis

A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset

Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only